Vaso Occlusive Crisis Market Size & Share, by Type (Gene Therapy, Supportive Care), End User (Outpatient Care, Pharmaceuticals, Inpatient Care) - Global Supply & Demand Analysis & Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5333
  • Published Date: Oct 19, 2023
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Vaso Occlusive Crisis Market size is anticipated to reach USD 20 billion by the end of 2036, growing at a CAGR of 8% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of vaso occlusive crisis was over USD 10 billion. Some medical devices, such as portable oxygen concentrators and home monitoring equipment, can help individuals with SCD manage their condition more effectively. Early diagnosis and monitoring of SCD and VOCs are crucial. Diagnostic tools include hemoglobin electrophoresis, genetic testing, and various blood tests to assess the disease's severity and identify potential triggers for vaso-occlusive crises. The Vaso-Occlusive Crisis market is an evolving field with ongoing research and development. The introduction of new therapies and advances in understanding the disease can significantly impact the market. Additionally, there is a growing focus on improving the overall quality of life for individuals with SCD by providing comprehensive care and support. This market is driven by both medical and technological advancements, as well as the increasing awareness of the challenges faced by those with sickle cell disease.

A vaso-occlusive crisis (VOC) is a common and painful complication of sickle cell disease (SCD). It occurs when sickle-shaped red blood cells block small blood vessels, leading to pain and tissue damage. SCD is a genetic blood disorder that affects hemoglobin, the molecule in red blood cells responsible for carrying oxygen throughout the body. When the hemoglobin becomes deoxygenated, it can cause red blood cells to change shape, becoming rigid and forming a characteristic sickle shape. The VOC market primarily encompasses healthcare products and services related to the diagnosis, treatment, and management of vaso-occlusive crises in individuals with sickle cell disease. This market is significant because SCD affects millions of people worldwide, particularly those of African, Mediterranean, Middle Eastern, and Indian descent

Vaso Occlusive Crisis Market.PNG
Get more information on this report: Request Free Sample PDF

Vaso Occlusive Crisis Sector: Growth Drivers and Challenges

Growth Drivers

  • Advancements in Medical Research: Advancements in medical research are pivotal to the growth of the vaso occlusive crisis market. Researchers and pharmaceutical companies are making significant strides in understanding the molecular mechanisms underlying SCD and VOC. This knowledge is leading to the development of more targeted and effective treatments. Promising therapies such as gene therapy and gene editing techniques are on the horizon, offering potential cures for SCD and thereby reducing VOC incidents. A study published in the New England Journal of Medicine shows that there is a surge in research and development activities focused on sickle cell disease (SCD), which is a primary cause of VOC. The study reveals that in recent years, there has been a 6% annual increase in clinical trials related to SCD and VOC treatment.
  • Telemedicine and Remote Monitoring: The adoption of telemedicine and remote monitoring is an additional growth driver in the VOC market. It has become especially significant in the wake of the COVID-19 pandemic, which prompted a rapid shift toward telehealth services. For individuals with SCD, telemedicine allows for regular check-ups, monitoring of vital signs, and timely interventions, reducing the need for in-person visits and hospitalizations. This enhances patient outcomes and contributes to cost savings in healthcare. The COVID-19 pandemic accelerated the adoption of telemedicine in healthcare. For patients with chronic conditions like SCD, telemedicine offers a convenient way to access care and monitor their condition remotely.
  • Personalized Medicine and Targeted Therapies: Personalized medicine is playing a pivotal role in the growth of the vaso occlusive crisis market. Advances in genomics and the understanding of individual genetic variations have enabled healthcare providers to tailor treatment plans to the unique genetic profiles of patients with sickle cell disease. This approach allows for more precise and effective therapies, reducing the occurrence of VOCs and their associated complications. By analyzing a patient's genetic makeup, healthcare professionals can identify specific genetic variants that influence the course of the disease and the likelihood of VOCs. For example, some individuals may benefit from hydroxyurea therapy, which increases the production of fetal hemoglobin, while others may be candidates for gene-based therapies that target the underlying genetic mutations responsible for SCD.


  • Limited Treatment Options: Despite advancements in the development of targeted therapies, the treatment options for SCD and VOCs remain limited. Many existing treatments focus on managing symptoms and do not address the underlying genetic causes of the disease. New drug development takes time, and there is a need for more innovative approaches to provide effective and accessible treatments. The primary approach to treating VOCs is pain management. Opioid medications are commonly used, but they come with the risk of addiction and may not be effective for all patients. Non-steroidal anti-inflammatory drugs (NSAIDs) can help with pain and inflammation but have their limitations.
  • Health Disparities and Access to Care
  • Lack of Awareness among Patients

Vaso Occlusive Crisis Market: Key Insights

Base Year


Forecast Year




Base Year Market Size (2023)

~ USD 10 Billion

Forecast Year Market Size (2036)

~ USD 20 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Vaso Occlusive Crisis Segmentation

Type (Gene Therapy, Supportive Care)

The supportive care segment in the vaso occlusive crisis market is estimated to gain the largest revenue share of 60% in the year 2036. Holistic patient-centered care focuses on addressing the physical, emotional, and psychosocial needs of individuals during VOCs. This approach emphasizes personalized care plans, pain management, nutritional support, and psychological assistance. A study published in the Journal of Pain and Symptom Management demonstrates the tangible benefits of this approach in improving the overall well-being and quality of life for individuals during VOCs. According to a study, patients receiving holistic, patient-centered care reported a 30% improvement in overall well-being and quality of life during VOCs. The growth of the supportive care segment in the vaso occlusive crisis market is driven by a holistic approach to patient-centered care, psychological support, pain management programs, nutritional support, remote monitoring, and personalized care plans. These drivers, supported by reliable statistics, collectively contribute to improved quality of life and outcomes for individuals with SCD during VOCs. Healthcare providers and policymakers must continue to invest in these areas to ensure comprehensive support for individuals with SCD.

End User (Outpatient Care, Pharmaceuticals, Inpatient Care)

Vaso occlusive crisis market from the outpatient care segment is expected to garner a significant share in the year 2036. Enhanced access to medications is a critical driver for outpatient care. It involves ensuring that patients have timely access to the necessary medications. The report by the American Society of Hematology demonstrates that improved access to medications has significantly reduced hospitalizations related to VOCs in outpatient settings, resulting in both cost savings and better patient care. Educational programs and patient empowerment initiatives aim to educate individuals with SCD about their condition and encourage active participation in their care. The Sickle Cell Disease Association of America's data highlights the positive impact of such programs in increasing patient adherence to treatment plans during VOCs, resulting in better self-management and health outcomes. The growth of the outpatient care segment in the vaso occlusive crisis marketis driven by the increasing adoption of telemedicine, personalized care plans, pain management programs, medication management, education and patient empowerment, and improved access to medications.

Our in-depth analysis of the global market includes the following segments


  • Gene Therapy
  • Supportive Care

End User

  • Outpatient Care
  • Pharmaceuticals
  • Inpatient Care

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Vaso Occlusive Crisis Industry - Regional Synopsis

APAC Market Forecast

The vaso occlusive crisis market in the Asia Pacific region is projected to hold the largest revenue share of 38% by the end of 2036. Collaborative research and clinical trials are accelerating advancements in SCD and VOC management. The combined efforts of academic institutions, healthcare providers, and pharmaceutical companies are driving innovation in the region. The Asia Pacific Society of Hematology's report underscores the significant growth in collaborative research and clinical trials in the Asia Pacific. The Asia Pacific Society of Hematology reports a 15% annual increase in collaborative research and clinical trials related to SCD and VOC management in the Asia Pacific region. The growth of the VOC market in the Asia Pacific region is propelled by increasing disease awareness, expanding newborn screening programs, access to innovative therapies, government initiatives and funding, telemedicine adoption, and collaborative research efforts. These drivers, supported by reliable statistics, collectively contribute to improved care and outcomes for individuals with SCD during VOCs in the Asia Pacific region. Continued investment and collaboration are essential to addressing the unique challenges and opportunities in this region.

North American Market Statistics

The vaso occlusive crisis market in the North America region is projected to hold the second-largest share during the forecast period. Advances in personalized medicine have significantly contributed to the improvement of SCD management in North America. This approach involves tailoring treatment plans to the unique genetic makeup of patients, allowing for more precise interventions. The study in the American Journal of Hematology underscores the effectiveness of personalized treatment in reducing the frequency of VOCs. A study reveals that personalized treatment strategies, based on individual genetic profiles, have led to a 35% reduction in the frequency of VOCs in patients with SCD in North America. Gene therapy and gene editing represent promising approaches in the treatment of SCD and VOCs.

North America is witnessing rapid growth in clinical trials, demonstrating the commitment to advancing these innovative therapies. The data from NIH highlights the substantial increase in such trials, showcasing the region's dedication to research in this field. Telemedicine and remote monitoring have become integral to healthcare in North America. These technologies allow patients to consult healthcare providers remotely, monitor vital signs, and receive timely interventions.

Research Nester
Vaso Occlusive Crisis Market size.PNG
Get more information on this report: Request Free Sample PDF

Companies Dominating the Vaso Occlusive Crisis Landscape

    •     Novartis Pharmaceuticals Corporation
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Bristol-Myers Squibb
    • Pfizer Inc.
    • Global Blood Therapeutics
    • AstraZeneca
    • Sanofi
    • GlaxoSmithKline
    • Regeneron Pharmaceuticals
    • Bluebird Bio
    • Emmaus Life Sciences, Inc.

In the News

  • Pfizer acquired Arena Pharmaceuticals for USD 6.7 billion. Arena is a clinical-stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases.
  • Pfizer announced a definitive agreement to acquire Seagen for USD 43 billion. Seagen is a global biotechnology company that discovers, develops, and commercializes transformative cancer medicines.

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 5333
  • Published Date: Oct 19, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Increasing demand for the pharmaceutical sector is the major factor driving the market growth.

The market size of vaso occlusive crisis is anticipated to attain a CAGR of 8% over the forecast period, i.e., 2024-2036.

The major players in the market are Novartis Pharmaceuticals Corporation, Bristol-Myers Squibb, Pfizer Inc., Global Blood Therapeutics, AstraZeneca, Sanofi, and others.

The outpatient care segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the Asia Pacific region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Vaso Occlusive Crisis Market Report Scope

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying